Ranibizumab biosimilar (Qilu Pharmaceutical)

雷珠单抗生物类似药（齐鲁制药）

Report date: 2024/08/19 17:03:56

Base Information

Drug NameRanibizumab biosimilar (Qilu Pharmaceutical)
Drug Alias Name雷珠单抗生物仿制药（齐鲁制药）重组抗VEGF人源化单克隆抗体（齐鲁制药）RimmyrahBCD-300QL-1205
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[10] 
Global Approved IndicationsDiabetes ComplicationsChoroidal NeovascularizationWet age-related macular degeneration +[6] 
Approved Indications in ChinaMacular Degeneration
Original Approved Country/TerritoryEU
Original Approved Date2024/01/05
Country/TerritoryCzechiaBulgariaUkraine +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiocndQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharma Spain SaQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeS01LA04
Related LinksN/A